Industry News
Pharmaceutical Industry News
Otsuka’s dispersible TB drug for kids wins CHMP support
Otsuka’s dispersible TB drug for kids wins CHMP support ntaylor Tue, 07/27/2021 - 06:17
AstraZeneca edges out in front of competition with FDA nod for once-weekly diabetes drug in kids
AstraZeneca edges out in front of competition with FDA nod for once-weekly diabetes drug in kids ntaylor Tue, 07/27/2021 - 06:11
‘Godmother of Soul’ joins pharma-backed campaign to boost cancer screenings after pandemic dropoff
‘Godmother of Soul’ joins pharma-backed campaign to boost cancer screenings after pandemic dropoff bbulik Mon, 07/26/2021 - 20:05
Vaccine Makers Are Asked to Expand Safety Studies on Children
The F.D.A. wants Pfizer and Moderna to increase the number of 5- to 11-year-olds who participate in trials of their coronavirus vaccines to ensure there is enough data about rare side effects.
As GlaxoSmithKline works to get Shingrix back on track, an FDA approval increases the key vaccine’s reach
As GlaxoSmithKline works to get Shingrix back on track, an FDA approval increases the key vaccine's reach esagonowsky Mon, 07/26/2021 - 16:08
Emergent’s new opioid awareness campaign taps NFL’s Darren Waller to tackle overdose stigma
Emergent's new opioid awareness campaign taps NFL's Darren Waller to tackle overdose stigma fkansteiner Mon, 07/26/2021 - 15:43
Pfizer, Johnson & Johnson settle high-profile Remicade biosim lawsuit on undisclosed terms
Pfizer, Johnson & Johnson settle high-profile Remicade biosim lawsuit on undisclosed terms kdunleavy Mon, 07/26/2021 - 11:36
Look out, Lilly: Biogen’s Aduhelm likely won’t be the only Alzheimer’s med subject to Medicare’s coverage review
Look out, Lilly: Biogen's Aduhelm likely won't be the only Alzheimer's med subject to Medicare's coverage review nhigginsdunn Mon, 07/26/2021 - 11:17
Better together: McCann and FCB health chiefs talk strategy and strengths in creating IPG Health
Better together: McCann and FCB health chiefs talk strategy and strengths in creating IPG Health bbulik Mon, 07/26/2021 - 10:33
Despite JAK ‘anxiety,’ ICER experts overwhelmingly back Incyte’s ruxolitinib cream in atopic dermatitis
Despite JAK 'anxiety,' ICER experts overwhelmingly back Incyte's ruxolitinib cream in atopic dermatitis fkansteiner Mon, 07/26/2021 - 10:16
Bristol Myers, yielding to FDA pressure, pulls Opdivo in post-Nexavar liver cancer
Bristol Myers, yielding to FDA pressure, pulls Opdivo in post-Nexavar liver cancer aliu Mon, 07/26/2021 - 05:47
Johnson & Johnson podría ser menos eficaz contra la variante delta
Muchos de los que recibieron la vacuna pueden necesitar refuerzos, dijeron los autores. Pero las autoridades sanitarias federales no recomiendan segundas dosis.
AstraZeneca’s newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says
AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says nhigginsdunn Fri, 07/23/2021 - 14:46
CDMO Recipharm continues its rapid expansion with a second fill-finish facility, this time in India
CDMO Recipharm continues its rapid expansion with a second fill-finish facility, this time in India kdunleavy Fri, 07/23/2021 - 11:44
Lumen plots site at nearby Seattle bakery as it ramps up production of algae-based biologics
Lumen plots site at nearby Seattle bakery as it ramps up production of algae-based biologics fkansteiner Fri, 07/23/2021 - 11:37
Meet the new GSK consumer health boss after spinoff, same as the old boss despite Elliott’s threat for change
Meet the new GSK consumer health boss after spinoff, same as the old boss despite Elliott's threat for change aliu Fri, 07/23/2021 - 10:24
Takeda lays out $126M to tap robotics, virtual reality and more at California production site
Takeda lays out $126M to tap robotics, virtual reality and more at California production site fkansteiner Fri, 07/23/2021 - 09:25
Pfizer-BioNTech sign on to provide 200 million more COVID-19 vaccine doses to the U.S.
Pfizer-BioNTech sign on to provide 200 million more COVID-19 vaccine doses to the U.S. kdunleavy Fri, 07/23/2021 - 09:21
Novartis on the hook for $178M after losing Tafinlar patent fight with Daiichi’s Plexxikon business
Novartis on the hook for $178M after losing Tafinlar patent fight with Daiichi's Plexxikon business kdunleavy Fri, 07/23/2021 - 07:13
Fierce Pharma Asia—Junshi’s mRNA JV; Novartis’ China business; Roche’s Ronapreve COVID nod in Japan
Fierce Pharma Asia—Junshi's mRNA JV; Novartis' China business; Roche's Ronapreve COVID nod in Japan aliu Fri, 07/23/2021 - 05:04